Accepted for Publication: May 8, 2014.
Published Online: September 1, 2014. doi:10.1001/jamaneurol.2014.1581.
Study concept and design: Pittock, Lennon, Barcellos.
Acquisition, analysis, or interpretation of data: Lennon, Bakshi, Shen, McKeon, Quach, Briggs, Bernstein, Schaefer, Barcellos.
Drafting of the manuscript: Pittock, Bernstein, Barcellos.
Critical revision of the manuscript for important intellectual content: Lennon, Bakshi, Shen, McKeon, Quach, Briggs, Schaefer, Barcellos.
Obtained funding: Pittock, Schaefer, Barcellos.
Administrative, technical, or material support: Lennon, Bakshi, Briggs, Bernstein.
Study supervision: Pittock, Schaefer, Barcellos.
Conflict of Interest Disclosures: Dr Pittock receives support from Alexion Pharmaceutical Inc and is a named inventor on patents that relate to functional aquaporin-4/neuromyelitis optica antibody assays and neuromyelitis optica antibodies as a cancer marker. Dr Pittock has provided consultation to Alexion Pharmaceutical, MedImmune LLC, and Chugai Pharma but has received no personal fees or compensation for these consulting activities. Dr Lennon is a named inventor on 2 patent applications filed by the Mayo Foundation for Medical Education and Research that relate to the neuromyelitis optica aquaporin-4 antibody, its application to cancer, and functional assays for detecting aquaporin-4 antibodies. Dr Lennon and the Mayo Clinic have received royalties that exceed the federal threshold for significant financial interest from licensing of the above listed technology and have rights to receive future royalties. Serological testing for neural autoantibodies is offered on a service basis by Mayo Collaborative Service Inc, an agency of the Mayo Foundation. Neither Dr Lennon nor her laboratory benefit financially from this testing. Dr McKeon receives support from MedImmun Inc. No other disclosures were reported.
Funding/Support: This work was supported by grants RO1 NS065829, R01 NS049510, and R01 ES017080 from the National Institutes of Health/National Institute of Neurological Disorders and Stroke, grant R01 AI076544 from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, and the Guthy-Jackson Charitable Foundation. Dr Pittock receives research support from the Guthy-Jackson Charitable Foundation and grant NS065829 from the National Institutes of Health. Dr Briggs is a postdoctoral fellow at the National Multiple Sclerosis Society. Dr McKeon receives research support from the Guthy-Jackson Charitable Foundation.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank John Schmeling, BS, Mayo Clinic, for performing aquaporin-4-IgG serological assays and for assistance with data analysis, Katie Cornelius, BS, Mayo Clinic, for technical assistance, and Jessica Sagen, BA, Mayo Clinic. None received financial compensation.